Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Arbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who decide whether treatment is appropriate. Compounded medications are prepared by licensed U.S. pharmacies for individual patients and are not reviewed by the FDA for safety or effectiveness.
Sources
- Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-286.
- ClinicalTrials.gov. SUSTAIN 7 (NCT02648204).
- DailyMed. Trulicity (dulaglutide) injection, prescribing information (revised March 2026).
- DailyMed. Ozempic (semaglutide) injection, prescribing information (June 2026).
- MedlinePlus. Dulaglutide injection. National Library of Medicine (revised August 2025).
- Frias JP, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus 1.5 mg (AWARD-11). Diabetes Care. 2021;44:765-773.
- Pratley RE, et al. An indirect treatment comparison of the efficacy of semaglutide 1.0mg versus dulaglutide 3.0 and 4.5mg. Diabetes Obes Metab. 2021;23:2513-2520.
- Lingvay I, et al. An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. J Clin Endocrinol Metab. 2022;107:1461-1469.
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1).
- DailyMed. Wegovy (semaglutide) injection and tablets, prescribing information (June 2026).
- The White House. Fact sheet: most-favored-nation pricing developments (November 2025).







